
InsuraGuest Reports 15% Gross Margin Growth and 54% Reduction in Net Loss Year-Over-Year
Vancouver, British Columbia--(Newsfile Corp. - May 28, 2025) - InsuraGuest Technologies, Inc.® (TSXV: ISGI) (OTCQB: ISGIF) ("InsuraGuest" or the "Company"), a leading innovator in the Insurtech space, has announced its financial results for the nine months ended March 31, 2025, highlighting significant growth and improved financial efficiency.
The Company achieved a 15% year-over-year increase in gross margin dollars driven by a $47,476 boost in revenue and an improvement in gross margin percentage from 61% to 65.8%. The expansion of vacation rental properties and a full nine months of revenue from our newest customer contributed to this upward trend. Additionally, strategic cost management efforts led to a 54% reduction in comprehensive loss, decreasing from $379,720 to $174,731.
"We continue to expand our vacation rental portfolio and enhance our insurtech solutions," says President Reed Wright. "Our technology stack and products are increasingly recognized as industry leaders in the vacation rental, hotel, and events sectors, fueling revenue growth and driving us towards profitability."
About InsuraGuest Technologies Inc.
Harnessing the Power of Technology to Reinvent Insurance
InsuraGuest Technologies (TSXV: ISGI) (OTCQB: ISGIF) is an innovative Insurtech company delivering insurance and warranty coverages to vacation rentals, hotels, resorts, and ticketed events. The Company offers tech-driven risk management solutions in the hospitality sector and continues to expand its offerings to meet market demands.
CA / LIC: 6001686
For more information, visit the company's website at: www.InsuraGuest.com
The Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions, and expectations. There is no assurance that this new business product offering or other planned products will be successful. The insurance and hospitality industries face increasing, and every-changing governmental regulation. The insurance industry is intensely competitive, and the Company's competitors have significantly more resources than the Company. Acceptance by potential customers is difficult to predict, particularly in the case of new products and disruptive technologies. If the Company fails to achieve market acceptance, this will significantly impact its results and financial resources. Achieving market acceptance may require advertising budgets that exceed the Company's current resources and require the Company to seek additional debt or equity financing. There is no assurance that such financing will be available at reasonable prices or at all.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBC
an hour ago
- CBC
Alberta asks for a West Coast pipeline as a nation-building project
The federal government has tabled a signature piece of legislation designed to invest in what Prime Minister Carney is referring to as 'nation-building projects.' The CBC's Sam Brooks takes us into how the Alberta government is responding.

National Post
an hour ago
- National Post
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
Article content VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass. — SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. Article content SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. Article content Article content 'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.' Article content 'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.' Article content About SOLVE FSHD Article content SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit Article content Article content Article content Article content Contacts Article content


CTV News
3 hours ago
- CTV News
Greater Sudbury sells home to Habitat for Humanity for $5
Greater Sudbury will transfer a vacant Melvin Avenue property to Habitat for Humanity for just $5 as part of its land bank strategy. The home, designated for a veteran's family, is near a park and bus stops. The non-profit says construction is expected within the year.